Core Viewpoint - A shareholder class action lawsuit has been filed against MoonLake Immunotherapeutics, alleging that the company made materially false and misleading statements regarding its product SLK and its comparison to monoclonal antibodies [1] Summary by Relevant Sections Allegations - The lawsuit claims that the defendants failed to disclose critical information about the differences between Nanobodies and monoclonal antibodies, specifically that: - SLK and BIMZELX target the same inflammatory cytokines IL-17A and IL-17F [1] - SLK's unique Nanobody structure does not provide a clinical benefit over BIMZELX's traditional monoclonal structure [1] - The supposed increased tissue penetration of SLK does not lead to improved clinical efficacy [1] - Defendants lacked a reasonable basis for their positive claims regarding SLK's superiority to monoclonal antibodies [1] Legal Information - Shareholders who purchased MoonLake shares between March 10, 2024, and September 29, 2025, and suffered significant losses are encouraged to discuss their legal rights [2] - The deadline to request appointment as lead plaintiff in the case is December 15, 2025 [3]

Core Points - A shareholder class action lawsuit has been filed against RCI Hospitality Holdings, Inc. alleging materially false and misleading statements regarding the company's business and operations [1] - The lawsuit includes allegations of tax fraud, bribery to cover up tax fraud, and an understatement of the legal risks facing the company [1] Legal Context - Shareholders who purchased RCI shares between December 15, 2021, and September 16, 2025, and experienced significant losses are encouraged to discuss their legal rights [2] - The deadline to request appointment as lead plaintiff in the case is November 20, 2025 [3]

Core Points - A shareholder class action lawsuit has been filed against Quantum Corporation alleging that the company made materially false and misleading statements regarding its financial practices [1] - The lawsuit claims that Quantum improperly recognized revenue for the fiscal year ended March 31, 2025, necessitating a restatement of financial statements for the fiscal third quarter ended December 31, 2024 [1] - The allegations suggest that the statements made by the defendants about Quantum's business, operations, and prospects were materially false and lacked a reasonable basis [1] Legal Information - Shareholders who purchased Quantum shares between November 15, 2024, and August 18, 2025, and suffered significant losses are encouraged to discuss their legal rights [2] - The deadline to request to be appointed as lead plaintiff in the case is November 3, 2025 [3] - Holzer & Holzer, LLC is representing shareholders in this litigation and has a history of recovering significant amounts for investors affected by corporate misconduct [3]

Core Points - A shareholder class action lawsuit has been filed against Nutex Health Inc. alleging materially false and misleading statements regarding its business and operations [1] - The lawsuit claims that Nutex's engagement with HaloMD involved a scheme to defraud insurance companies, leading to unsustainable revenue [1] - Allegations include overstating the remediation of internal control weaknesses and improper accounting of stock-based compensation obligations [1] - The lawsuit suggests that these issues increased the risk of Nutex failing to file timely financial reports with the SEC, thereby overstating its business and financial prospects [1] Legal Context - Shareholders who purchased Nutex shares between August 8, 2024, and August 14, 2025, and experienced significant losses are encouraged to discuss their legal rights [2] - The deadline to request lead plaintiff status in the lawsuit is October 21, 2025 [3] - Holzer & Holzer, LLC is representing shareholders and has a history of recovering significant amounts for victims of corporate misconduct [3]

Core Viewpoint - A shareholder class action lawsuit has been filed against Altimmune, Inc. alleging that the company made materially false and misleading statements regarding the results of the IMPACT Phase 2b MASH trial, particularly concerning inflated expectations and undisclosed adverse information related to the placebo group's responses [1] Group 1: Lawsuit Details - The lawsuit claims that Altimmune consistently promoted inflated expectations for positive topline results from the IMPACT Phase 2b MASH trial [1] - It is alleged that the company concealed higher responses in the placebo group, which could negatively impact the topline results [1] Group 2: Shareholder Information - Shareholders who purchased Altimmune shares between August 10, 2023, and June 25, 2025, and experienced significant losses are encouraged to discuss their legal rights [2] - The deadline for shareholders to request to be appointed as lead plaintiff in the case is October 6, 2025 [3] Group 3: Legal Representation - Holzer & Holzer, LLC is a law firm specializing in securities litigation and has a history of recovering significant amounts for shareholders affected by corporate misconduct [3] - The firm has been recognized as an ISS top-rated securities litigation law firm for 2021, 2022, and 2023 [3]

Core Points - A shareholder class action lawsuit has been filed against SelectQuote, Inc. alleging misconduct related to Medicare beneficiaries [1] - The lawsuit claims SelectQuote directed beneficiaries to insurers that compensated the company best, rather than based on plan quality [1] - Allegations include failure to provide unbiased comparisons, receiving illegal kickbacks, and non-compliance with laws and regulations [1] - The lawsuit suggests that SelectQuote's positive statements about its business were materially misleading [1] Legal Context - Shareholders who purchased SelectQuote shares between September 9, 2020, and May 1, 2025, and suffered losses are encouraged to discuss their legal rights [2] - The deadline to request lead plaintiff status in the case is October 10, 2025 [3] - Holzer & Holzer, LLC is representing shareholders and has a history of recovering significant amounts for victims of corporate misconduct [3]

Core Points - A shareholder class action lawsuit has been filed against Flywire Corporation, alleging that the company made materially false and misleading statements regarding its revenue growth and the impact of permit and visa-related restrictions on its business [1] - The lawsuit claims that the strength and sustainability of Flywire's revenue growth was overstated, and the negative impacts of regulatory restrictions were understated [1] - The lawsuit indicates that these misleading statements were made at all relevant times, affecting the company's public perception and potentially its stock performance [1] Legal Information - Shareholders who purchased Flywire shares between February 28, 2024, and February 25, 2025, and experienced significant losses are encouraged to discuss their legal rights [2] - The deadline for shareholders to request to be appointed as lead plaintiff in the case is September 23, 2025 [3] - Holzer & Holzer, LLC is representing the shareholders in this litigation and has a history of recovering significant amounts for investors affected by corporate misconduct [3]

Core Points - A shareholder class action lawsuit has been filed against Fortrea Holdings, Inc. alleging that the company made materially false and misleading statements regarding its business and financial prospects [1] - The lawsuit claims that Fortrea overestimated revenue contributions from Pre-Spin Projects and overstated cost savings from exiting transition services agreements [1] - As a result of these allegations, Fortrea's previously announced EBITDA targets for 2025 are said to be inflated, raising concerns about the viability of its post-Spin-Off business model [1] Legal Context - Shareholders who purchased Fortrea shares between July 3, 2023, and February 28, 2025, and suffered significant losses are encouraged to discuss their legal rights [2] - The deadline for shareholders to request to be appointed as lead plaintiff in the case is August 1, 2025 [3] - Holzer & Holzer, LLC is representing shareholders in this litigation and has a history of recovering significant amounts for investors affected by corporate misconduct [3]

Core Points - A shareholder class action lawsuit has been filed against Open Lending Corporation, alleging that the company made materially false and misleading statements regarding its business and operations [1] - The lawsuit claims that Open Lending misrepresented the capabilities of its risk-based pricing models and issued misleading statements about its profit share revenue [1] - It is alleged that Open Lending failed to disclose that its 2021 and 2022 vintage loans were worth significantly less than their outstanding loan balances [1] - The lawsuit also claims that the company misrepresented the underperformance of its 2023 and 2024 vintage loans [1] Legal Context - Shareholders who purchased Open Lending shares between February 24, 2022, and March 31, 2025, and suffered significant losses are encouraged to discuss their legal rights [2] - The deadline to request to be appointed lead plaintiff in the case is June 30, 2025 [3] - Holzer & Holzer, LLC is representing shareholders in this litigation and has a history of recovering significant amounts for shareholders affected by corporate misconduct [3]